ÂÜÀòÂÒÂ×

Dr. Ulrich Rodeck currently serves as Vice Chair and Professor of Dermatology and Professor of Radiation Oncology at Thomas Jefferson University and is a scientific co-founder of Xilio Therapeutics. His research efforts over the last 30 years have focused on improving cancer therapy by leveraging immune effector mechanisms. In addition, his laboratory has investigated skewing of immune responses by tumor-derived cytokines and, as of recently, exploiting immunogenic cell death induced by radiation in combination immunotherapies, including tumor vaccine and checkpoint modifiers. Collectively, his work has been published in more than 135 peer-reviewed research reports and more than 30 reviews. Dr. Rodeck served as the PI on NIH and DoD-funded projects and currently receives support from the Department of Defense, foundations and the pharmaceutical industry. Xilio’s proprietary technology is licensed from City of Hope and Thomas Jefferson University. Dr. Rodeck earned a Ph.D. in Immunology from the University of Hamburg and an M.D. from the University of Münster in Germany.